Industry News

Bayer has announced promising new findings showing that finerenone, its non-steroidal mineralocorticoid receptor antagonist, significantly lowers the risk of chronic kidney disease (CKD) progression and major cardiovascular complications across a broad range of patients living with CKD. The latest results were presented during the 63rd European Renal Association (ERA) Congress.

Glenmark Pharmaceuticals Ltd. has announced that its U.S.-based subsidiary, Glenmark Pharmaceuticals Inc., USA, has launched Lacosamide Injection USP 200 mg/20 mL (10 mg/mL) Single-Dose Vials in the United States market. The product is the generic equivalent of Vimpat Injection marketed by UCB Inc. and is indicated for the treatment of seizures associated with epilepsy.

In a move aimed at improving access to diabetes and obesity treatment, Alkem Laboratories has launched India's first semaglutide single-shot pre-filled syringes, with prices starting at just ₹350.

The launch marks another milestone in the rapidly evolving obesity and diabetes care market, as Alkem continues to expand its semaglutide portfolio following the introduction of pre-filled disposable and reusable injection pens earlier this year.

Gilead Sciences has announced positive results from its Phase 3 IDEAL trial evaluating Livdelzi (seladelpar)in adults with primary biliary cholangitis (PBC), a rare chronic autoimmune liver disease. The study met its primary endpoint, demonstrating statistically significant improvement in a composite measure of alkaline phosphatase (ALP) normalization compared with placebo.

The Serum Institute of India (SII) has joined hands with the University of Oxford and the Coalition for Epidemic Preparedness Innovations (CEPI) to accelerate the development of an experimental vaccine targeting the Bundibugyo strain of Ebola virus, a deadly pathogen currently driving outbreaks in the Democratic Republic of Congo (DRC) and Uganda. CEPI has committed up to 8.6 million USD to support the vaccine's advancement toward clinical testing.

Shares of Indoco Remedies gained 4.12% on Friday after the company announced that its Oral Solid Dosage (OSD) manufacturing facility at Baddi, Himachal Pradesh, has received European Union Good Manufacturing Practice (EU GMP) certification from the German Health Authority, Berlin. The regulatory approval is expected to strengthen the company's position in regulated European markets and has been welcomed positively by investors.

Global biotechnology company Regeneron Pharmaceuticals has announced plans to establish its first Global Capability Centre (GCC) outside the United States in Hyderabad, further strengthening Telangana's position as a leading destination for global life sciences and technology investments.